Rezolute, Inc. (6HV1)
XDUS 
Summary
6HV1 Chart
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?
Rezolute rises 38% in a week after interim upLIFT data shows most tumor HI patients cut or eliminate IV glucose support.
Rezolute Stock Gains After FDA Meeting on Ersodetug Program Update
RZLT stock jumps 12% after an FDA meeting highlights ersodetug data and next steps, despite an earlier phase III setback in the congenital HI study.
RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know
Rezolute shares collapse 79% so far in December after a phase III hyperinsulinism study of its only pipeline candidate miss primary and key secondary endpoints.
Rezolute, Inc. (6HV1) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Rezolute, Inc. ever had a stock split?
Rezolute, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Nevan Charles Elam CEO | XDUS Exchange | US76200L3096 ISIN |
| US Country | 64 Employees | - Last Dividend | 13 Oct 2020 Last Split | 1 May 2014 IPO Date |
Overview
Rezolute, Inc. is a clinical stage biopharmaceutical company that focuses on the development of novel therapies for metabolic diseases characterized by chronic glucose imbalance. Based in the United States, specifically in Redwood City, California, the company has established a significant presence in the field of metabolic disease therapy research and development since its inception in 2010. Originally known as AntriaBio, Inc., the company underwent a rebranding phase and adopted its current name, Rezolute, Inc., in December 2017. The strategic shift in branding reflects the company’s commitment to revolutionizing the treatment of metabolic diseases with innovative therapeutic solutions.
Products and Services
- RZ358
RZ358 is positioned as Rezolute, Inc.'s flagship product candidate, exemplifying the company's innovative approach to treating metabolic conditions. It is a human monoclonal antibody currently undergoing a Phase 2b clinical trial. This investigational therapy targets congenital hyperinsulinism, an ultra-rare genetic disorder in pediatric patients that results in excessive insulin release. The potential of RZ358 lies in its unique mechanism of action, designed to restore normal blood glucose levels by modulating the activity of insulin, thereby offering a targeted therapeutic approach for this challenging condition.
- RZ402
Expanding its portfolio into diseases associated with diabetes, Rezolute is developing RZ402, an oral plasma kallikrein inhibitor. Currently in the clinical trial phase, RZ402 is aimed at the chronic treatment of diabetic macular edema, a significant cause of vision loss in diabetic patients. By inhibiting the kallikrein-kinin system, RZ402 has the potential to reduce vascular permeability and inflammation within the retina, addressing a critical unmet need in the management of diabetic eye diseases and embodying Rezolute’s commitment to improving the lives of individuals with diabetes-related complications.
